EN DE
Watch CONMED Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CONMED Corporation (CNMD) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of CONMED Corporation stock $34.74, price $51.50, that is 32.5% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CC CONMED Corporation logo Broad data Nov 4, 2026

CONMED Corporation

CNMD · US
Solid, but expensive

Our calculation puts a fair price 33% below what the stock costs today.

Healthy Growth (revenue 5y +9.8 %/yr in USD)
Generates free cash flow
0.8% dividend yield · Well covered
Positive coverage
Broad data
Quality 58/100
Thin margins · 4.1% net margin (TTM)
Moderate debt
Mixed vs. peers (6/14)
Fair value $34.74 · Overvalued (−32.5%)
Narrow moat 39/100 · thin data
Watch CONMED Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$151.17 $32.11 Fair Value $34.74 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $32.11 – $151.17 · fair‑value band $22.68 – $53.12 · the $51.50 price screens above the $34.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow CONMED in your weekly email

Every Wednesday you see whether CONMED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.

Show moreShow less

The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.

It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name.

In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories.

Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads.

It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Stock analysis

CONMED Corporation (CNMD) currently trades at $51.50, while our model-based Fair Value estimate is $34.74, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $50.02 per share, and 6 of the 24 models we run sit above the $51.50 price.

Bear case: the Dividend Discount group reads lowest at $10.93, and 18 of the 24 models stay below the price. Data coverage for this calculation is high.

Scenario range: $22.68 (bear) to $53.12 (bull), the price of $51.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

CONMED Corporation reported revenue of $1.4B in FY2025 versus $1.0B in FY2021, a compound +8.0%/yr. Reported net income was $47.1M in FY2025, compounding −6.9%/yr from FY2021.

Key figures

Market cap $1.6B Small · P/E ratio 27.8 · P/S ratio 1.13 · EPS (TTM) $1.85 · Dividend yield 0.8% · Net margin 4.1% · Return on equity 5.5% · Return on assets (EBIT) 5.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 4% below its 52-week high and 60% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −33%, CNMD screens richer than that median.

Fair Value models

Bear $22.68 Fair Value $34.74 Bull $53.12
Price $51.50 · Downside -32.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.24 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $30.06 $57.73 $95.66 78
Growth DCF $30.13 $53.70 $83.75 77
Residual Income $24.64 $24.32 $25.05 76
All 24 models by family
DCF Models
FCF DCF $30.06 $57.73 $95.66 78
Owner Earnings $10.60 $28.74 $53.62 72
5Y Revenue Exit $20.58 $46.02 $78.34 69
5Y EBITDA Exit $36.49 $76.42 $123.47 73
5Y P/E Exit $9.81 $25.45 $41.62 68
10Y Revenue Exit $22.68 $45.73 $76.65 64
10Y EBITDA Exit $33.12 $65.17 $108.64 66
10Y P/E Exit $17.48 $32.56 $50.61 62
Earnings-Based
Graham-Dodd $10.68 $36.90 $49.56 64
Lynch FV $8.53 $12.19 $15.85 61
PEG = 1.0 $8.53 $12.19 $15.85 57
EPV $4.61 $8.83 $12.34 71
Dividend Discount
Gordon GGM $6.39 $11.46 $15.73 68
DDM Multi-Stage $6.39 $10.39 $12.25 67
Multiples
P/E Multiple $25.92 $34.56 $43.20 63
P/S Multiple $20.03 $26.71 $33.38 58
EV/EBIT $33.56 $53.59 $73.62 64
EV/EBITDA $49.00 $74.18 $99.35 66
EV/Revenue $16.37 $34.74 $53.12 51
Growth DCF
Growth DCF $30.13 $53.70 $83.75 77
Rev-Margin DCF $20.58 $46.34 $76.92 70
Economic Profit
Residual Income $24.64 $24.32 $25.05 76
ROIC Compounder $4.61 $8.83 $12.34 70
Growth Earnings
Growth-Adj P/E $22.12 $31.61 $41.09 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 35
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 73
Do the profits arrive as real cash?
Financial strength 40
Debt, balance sheet and risk of trouble
Investment 80
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 59
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 71
Distance to the 52-week high, does not count
New shares 99
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleRichard GlazeChief Information Officer257 shares at $41.21$10,591Nov 21, 202510b5-1 plan

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +6.7% a year
Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+14.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.8%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.9.3% vs 3.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.6% a year for the price and +0.8% for the forecasts.
Forecast 2026 (sales)−0.8%
Forecast 2027 (sales)+4.7%
Projected 2028 (sales)+4.4%
Projected 2029 (sales)+4.1%
Projected 2030 (sales)+3.7%

CNMD screens overvalued: fair value 33% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare CONMED Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −32.5% · Below median
Profitability
Return on equity (12 months) 5.5% · Above median
Return on assets 2.0% · Below median
Net margin (12 months) 4.1% · Below median
Operating margin (12 months) 14.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.3% · Below median
Dividend yield (12 months) 0.8% · Bottom 25%
Balance sheet
Debt / equity 0.81× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 27.8× · Pricier than median
P/B 1.50× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.13× · Cheapest 25%
Price / free cash flow (fiscal year) 10.3× · Cheapest 25%
EV/EBITDA 10.3× · Cheaper than median
PEG 1.84× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)2 · sector 35
PAST (return on equity)22 · sector 17
HEALTH (low debt)60 · sector 98
DIVIDEND (yield)16 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs CNMD
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs CNMD
DexCom, Inc DXCM $79.41 $87.35 +10% vs CNMD
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs CNMD
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs CNMD
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs CNMD
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs CNMD
Abbott Laboratories, ABT $109.93 $75.28 −32% vs CNMD
Medtronic plc MDT $101.80 $65.61 −36% vs CNMD
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs CNMD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CONMED Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CONMED Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CNMD

Frequently asked questions

Is CONMED Corporation (CNMD) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $34.74 versus a price of $51.50, about 33% lower (overvalued).
What is the fair value of CNMD?
Our model-based fair value for CONMED Corporation is $34.74 (as of Nov 4, 2026), built from audited fundamentals. The current price: $51.50.
What is the quality score of CNMD?
CONMED Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CONMED Corporation (CNMD)?
Our model-based price target is the fair value of $34.74 (as of Nov 4, 2026) from 24 valuation models. Cautious scenario $22.68, optimistic scenario $53.12. It is a calculation from audited fundamentals, not an analyst target.
What is the CONMED Corporation stock forecast for 2026?
Our models put fair value at $34.74, about 33% lower versus a price of $51.50 (overvalued). Cautious scenario $22.68, optimistic scenario $53.12. The calculation is refreshed regularly with new filings.
What is the revenue of CONMED Corporation (CNMD)?
CONMED Corporation reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Nov 4, 2026).
Does CONMED Corporation pay a dividend?
CONMED Corporation currently shows a dividend yield of 0.78% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of CONMED Corporation (CNMD) and when is the ex-dividend date?
CONMED Corporation pays a dividend of $0.4 per share a year, a dividend yield of 0.8%. The last ex-dividend date was Sep 15, 2025. A dividend has been paid every year since at least 2012. The payout ratio is 17.6% of earnings (on adjusted earnings, reported 21.6%). Free cash flow covers the dividend 12.59 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into CONMED Corporation (CNMD)?
For today's price to be fair in a discounted-cash-flow model, CONMED Corporation would have to grow free cash flow by +8.1 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of CNMD use?
Our models discount CONMED Corporation at 11.1 %: a base by market capitalisation (small), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CONMED Corporation that is +8.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has CONMED Corporation (CNMD) delivered so far?
Over the past 5 years revenue at CONMED Corporation grew +9.8 % a year. The price currently implies free-cash-flow growth of +8.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CONMED Corporation (CNMD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into CONMED Corporation (+8.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CONMED Corporation (CNMD)?
The free-cash-flow yield on the price is 9.73 %: that much free cash flow CONMED Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CONMED Corporation (CNMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CONMED Corporation it is $34.74 per share (as of Nov 4, 2026), against a price of $51.50. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is CONMED Corporation stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CNMD trades above its calculated fair value: price $51.50, fair value $34.74, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNMD?
No. The price is what the market pays today ($51.50); the fair value is what the company's own numbers justify ($34.74). For CONMED Corporation the two are $16.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is CONMED Corporation worth?
The market values CONMED Corporation at about $1.6B (market capitalisation, as of Nov 4, 2026). Per share that is $51.50; our models calculate a fair value of $34.74 per share.
What do the bullish and bearish scenarios say about CNMD?
Our models span a range for CONMED Corporation: cautious scenario $22.68, base $34.74, optimistic $53.12 per share (as of Nov 4, 2026, price $51.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CNMD?
CONMED Corporation trades at a price-to-earnings ratio of 27.8 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $34.74 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 27.8 (reported for FY2025: 34.1). Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2016, FY2017, FY2023 ex one-offs: 58.5. Other multiples: PEG 1.8, P/B 1.5, P/S 1.1, EV/EBITDA 10.3.
What is the PEG ratio of CNMD?
The PEG ratio of CONMED Corporation is 1.84 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of CONMED Corporation (CNMD)?
Balance-sheet figures for CONMED Corporation (as of Nov 4, 2026): return on equity 5.5%, debt of 0.81 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is CNMD from its 52-week high?
CONMED Corporation trades at $51.50, about 4% below its 52-week high of $53.66 and 60% above the low of $32.11 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $34.74 is for.
Which stocks are comparable to CONMED Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CONMED Corporation stock attractive at the current price?
The data as of Nov 4, 2026: price $51.50, calculated fair value $34.74 (−33%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNMD calculated?
We run CONMED Corporation through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $34.74 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. CONMED Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CONMED Corporation (CNMD)?
The closing price on Nov 6, 2026 was $51.50. Our model-based fair value is $34.74, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CONMED Corporation right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($22.68 to $53.12) leaves room in how you read the outcome.
Where does the earnings growth of CONMED Corporation (CNMD) come from?
Earnings per share at CONMED Corporation grew +12.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.2 %, EBIT margin +7.0 %, tax rate +1.2 %, residual (interest, one-offs) −1.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of CONMED Corporation

How large is the market capitalisation of CONMED Corporation (CNMD)?
The market capitalisation of CONMED Corporation is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CONMED Corporation (CNMD)?
The price-to-sales ratio of CONMED Corporation is 1.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CONMED Corporation (CNMD)?
Earnings per share at CONMED Corporation are $1.85 (price ÷ EPS = P/E 27.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CONMED Corporation (CNMD)?
The dividend yield of CONMED Corporation is 0.8% (payout 17.6%, on adjusted earnings, reported 21.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CONMED Corporation (CNMD)?
The net margin of CONMED Corporation is 4.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CONMED Corporation (CNMD)?
The return on equity (ROE) of CONMED Corporation is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CONMED Corporation (CNMD)?
On an EBIT basis the return on assets of CONMED Corporation is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CONMED Corporation (CNMD)?
The operating margin of CONMED Corporation is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CONMED Corporation (CNMD)?
Revenue at CONMED Corporation is growing +0.3% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CONMED Corporation (CNMD)?
Earnings per share at CONMED Corporation are growing +11.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CONMED Corporation (CNMD) carry?
The net debt of CONMED Corporation is $794M (fiscal year 2025, ≈ 5.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CONMED Corporation in the live analysis

One click puts CONMED Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.